

CONNECTING PATIENTS TO MEDICATION

The WD Rx Access program helps make it easier for patients who are prescribed Syprine® (trientine hydrochloride) or Cuprimine® (penicillamine) to have affordable access to the medication they need with:

- Copay Assistance: WD Rx Access provides copay assistance through a network of Specialty Pharmacies.
 - Patients who have commercial insurance may be eligible* to receive the prescribed product for as little as \$25
- **Prescription management:** WD Rx Access representatives will connect patients to a specialty pharmacy that will coordinate fulfillment of their prescription

Patient Assistance: For patients facing financial challenges in filling their SYPRINE® or CUPRIMINE® prescription, Valeant Pharmaceuticals has a Patient Assistance Program (PAP). The PAP is subject to eligibility requirements.* To enable WD Rx Access to determine a patient's eligibility for PAP, the following documentation must be provided:

- Completed WD Rx Access enrollment form (with patient and provider signatures) and prescription
- Documentation of household income (acceptable forms of income documentation include the patient's IRS 1040 form from the most recent tax year, W-2, or Social Security Benefit Statement)
- Proof of legal US residency (United States, Puerto Rico, or the US Virgin Islands)

ENROLLMENT FORM REQUIREMENTS

All services offered by WD Rx Access **require a completed enrollment form** containing both patient and prescribing healthcare provider signatures. Completed enrollment forms can be mailed or faxed to:

WD Rx Access

PO Box 220667, Charlotte, NC 28222-0667 **Fax:** (855) 735-4624

After reviewing your enrollment form, WD Rx Access will notify you and your physician by mail of your eligibility determination. If you have any questions about the program or application process, please call **(888) 607-7267**. WD Rx Access representatives are available Monday through Friday, 8:00 AM – 6:00 PM, Eastern Time.

Please see Boxed Warning for Cuprimine® below regarding the risk of toxicity, and accompanying full Prescribing Information.

WARNING FOR CUPRIMINE®

Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.

Please see accompanying full Prescribing Information for Syprine® Capsules.

*This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan or any other federal or state health care programs. These patients may qualify for alternative financial assistance. These offers are only good for use with Syprine® and Cuprimine®. No other purchase necessary. These offers are not health insurance. These offers are not transferable. These offers are not valid with other offers. These offers have no cash value. The patient understands and agrees to comply with the terms and conditions of these offers. Program term eligibility expires December 31, 2018. Valeant Pharmaceuticals reserves the right to rescind, revoke, terminate, or amend these offers at any time, with or without notice. For more information, call a WD Rx Access representative at 888-607-7267.

Syprine and Cuprimine are trademarks of Valeant Pharmaceuticals, International, Inc. or its affiliates. © 2017 Valeant Pharmaceuticals North America LLC





Enrollment Form – Page 1 of 2

ATTENTION: THE PATIENT INFORMATION SECTION MUST BE COMPLETED PRIOR TO THE HEALTHCARE PROVIDER FILLING OUT THE PROVIDER CERTIFICATION SECTION

Return this completed application with a valid prescription to: WD Rx Access, PO Box 220667, Charlotte, NC 28222-0667; or by fax: (855) 735-4624

	DDECODIDATION	ODNANTION		
	PRESCRIPTION INF	ORMATION		
Check the product for which you are requesting assistance: Syprine® (trientine hydrochloride) Sig		Cuprimine® (penicillamine) Sig		
Check the specialty pharmacy you wou	uld like to fill your prescription: AllianceRx Walgreens Prime	Accredo Health	Group, Inc.	US Bioservices
	PATIENT INFOR	MATION		
Patient Name:		SS #:	DOB: _	
Address:				
Day Phone #:				
$\hfill \square$ Yes, I authorize messages to be left on	my voicemail regarding the information	n I've provided and the	e status of my presc	cription.
DELIVERY INFO	RMATION (Please indicate shi	pping address if	different from	above)
Address:				
Delivery Contact Name:				
,	CE INFORMATION (Complete		-	
	•	or include define	grapine sneet,	
Primary Insurance (Include Medicare info Insurance Company Name:		Policy ID #		Group #:
· ·				
		Subscriber Name: Date of Birth: Rx Card Phone #:		
Secondary Insurance (Include Medicare i		To Cara	THORE #:	
Insurance Company Name:		Policy ID #:		Group #:
· ·	Subscriber Name:		•	
		Rx Card Phone #:		
l l	FINANCIAL INFORMATION (F	Patient assistance	only)	
Current gross annual household income: \$ Income Verification Source: 1040	Number of mer W-2 Social Security Benefit State Social Security Benefit State St	mbers in household: ment on provided in this app any free product, app irrams (such as medical ent is responsible for re ance in the form of free right at any time, and	olication is complete roval is not valid fo assistance program eporting receipt of the product is contine	r prescriptions reimbursed ns). Program approval is not this offer to any health insurer gent upon my ability to meet
	PATIENT AUTHORIZAT	ION (Required)		
I authorize my healthcare providers and he ("Valeant") to: (1) establish my eligibility for care; and (3) provide support services included federal privacy laws may no longer restrict permitted by law. I further understand I may refuse to sign the eligibility for health plan benefits or my trein my insurance status and understand tha	or benefits through WD Rx Access; (2) or ading facilitating the provision of produ- its further disclosure. Valeant agrees to his authorization and that my healthcare eatment on whether I sign this authorize	communicate with my luct to me. I understand ouse and disclose this e providers and health ation. I agree to immed	nealthcare providers I that once my PHI I information only for plans may not cond diately notify WD R	s and me about my medical has been disclosed to Valeant or the above purposes and as dition my enrollment in or x Access of any change

Syprine and Cuprimine are trademarks of Valeant Pharmaceuticals, International, Inc. or its affiliates. Any other product/brand names and/or logos are trademarks of the respective owners. © 2017 Valeant Pharmaceuticals North America LLC

Date: _



Patient Signature: _



Enrollment Form - Page 2 of 2

	PR	OVIDER INFORMATION		
Provider Name:		NPI #:	DEA #: _	
Tax ID #/Provider ID #:		State License #:		
Site/Facility Name:				
Street Address:				
City:			State:	Zip:
Phone #:	Fax #:	Contact Nai	me:	
		ON (Please attach valid pr	escription to form)	
Diagnosis Code(s):				
	PROVIDE	ER CERTIFICATION (Requi	red)	
and I will be supervising the pa and representatives of my patie and its agents and representati WD Rx Access and to otherwise obtained. I understand that if n and I agree to immediately not patients (or any third party), in change results in reimbursement that in such event Valeant will be under no obligation to prescrib prescribing product.	tient's treatments. I have obtain ent's identification and insurance wes to verify my patient's insura e administer WD Rx Access. I ur ny patient's insurance status cha ify WD Rx Access if I become a whole or in part, for product ob at to me for product supplied the bill me for the reimbursement product of	to the best of my knowledge. I cented from my patient all required a se information. I understand that a nce coverage and to assess, if appropriate and the second of the	uthorizations for the releny information provided plicable, patient's eligibi Rx Access does not gua ligible for the patient as certify that I will not bill nat if a retroactive insure notify a WD Rx Access ible for payment of the I	ease to Valeant and its agents I is for the sole use of Valeant ility for participation in trantee that assistance will be sistance program ("PAP"), for or accept payment from or claim decision or policy representative, and I understance bill. I understand that I am
Check box to commin your agre	sement to receiving taxes from	AND IX Access [
Provider Signature:			Date:	
Supervising Physician:				

No stamps. Physician signature required.

NY prescriptions must be submitted on NY State Rx form.

This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan or any other federal or state health care programs. These patients may qualify for alternative financial assistance. These offers are only good for use with Syprine® and Cuprimine®. No other purchase necessary. These offers are not health insurance. These offers are not transferable. These offers are not valid with other offers. These offers have no cash value. The patient understands and agrees to comply with the terms and conditions of these offers. Program term eligibility expires December 31, 2018. Valeant Pharmaceuticals reserves the right to rescind, revoke, terminate, or amend these offers at any time, with or without notice. For more information, call a WD Rx Access representative at 888-607-7267.

Cuprimine and Syprine are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates. Any other product/brand names and/or logos are trademarks of the respective owners.

© 2017 Valeant Pharmaceuticals North America LLC

